{
    "clinical_study": {
        "@rank": "168334", 
        "acronym": "INHALE", 
        "arm_group": {
            "arm_group_label": "Indacaterol/QAB149", 
            "description": "Patients treated with Indacaterol for COPD prior to enrollment in study"
        }, 
        "brief_summary": {
            "textblock": "A prospective observational multi centre research study in GP practices clustered within  up\n      to 10 UK Primary care trusts."
        }, 
        "brief_title": "Study of the Impact of Indacaterol (Onbrez\u00ae) on the Individual Lives and Health Status of Patients With COPD", 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with active diagnosis of COPD, confirmed by spirometry documented in medical\n             notes\n\n        Exclusion Criteria:\n\n          -  Patients who are currently receiving other maintenance therapy (except LAMA) for\n             COPD.\n\n          -  Patients previously prescribed Indacaterol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients will be recruited only after indacaterol has been prescribed and is being used\n        for the patients first maintenance therapy for COPD symptoms."
            }
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123199", 
            "org_study_id": "CQAB149BGB01"
        }, 
        "intervention": {
            "arm_group_label": "Indacaterol/QAB149", 
            "intervention_name": "Indacaterol (Onbrez\u00ae) /QAB149", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "COPD", 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Novartis Investigative Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Observational Study of the Impact of Indacaterol (Onbrez\u00ae) on the Individual Lives and Health Status of Patients With COPD", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Research Ethics Committee"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in COPD assessment Test (CAT Score) at 6-8 weeks after the initiation of indacaterol", 
            "safety_issue": "No", 
            "time_frame": "6-8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123199"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in COPD Assessment test (CAT) score at 6 months after the initiation of indacaterol", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Impact of indacaterol on patients' lies at 6 - 8 weeks after the initiation of indacaterol.", 
                "safety_issue": "No", 
                "time_frame": "6-8 weeks"
            }, 
            {
                "measure": "Physician Global Evaluation of Treatment   effectiveness (GETE) at 6-8 weeks and 6 months.", 
                "safety_issue": "No", 
                "time_frame": "6-8 weeks and 6 months"
            }, 
            {
                "measure": "Patient Global Evaluation of Treatment   effectiveness (GETE) at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}